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Myosin I isozymes have been implicated in various motile processes, including organelle translocation, ion-channel
gating, and cytoskeleton reorganization. Unconventional myosins were among the first family of proteins found
to be associated with hearing loss in both humans and mice. Here, we report the identification of a nonsense
mutation, of a trinucleotide insertion leading to an addition of an amino acid, and of six missense mutations in
MYO1A cDNA sequence in a group of hearing-impaired patients from Italy. MYO1A, which is located within the
DFNA48 locus, is the first myosin I family member found to be involved in causing deafness and may be a major
contributor to autosomal dominant–hearing loss.
Nonsyndromic hearing loss is the most common form of
genetic deafness. Approximately 15%–20% of cases are
transmitted as nonsyndromic autosomal dominant de-
fects (NSAD), for which 140 different loci have been
described and 17 genes identified (Hereditary Hearing
Loss Homepage; Petersen 2002). Recently, we reported
the mapping of a novel NSAD locus, DFNA48, to chro-
mosome 12q13-q14 in a large multigenerational Italian
family (D’Adamo et al. 2003).
The DFNA48 region contains, among others, integrin
genes, the retinoic acid receptor gamma gene (RARG
[MIM 180190]), the prefoldin 5-chaperone gene (PFDN5
[MIM 604899]), the class I myosin MYO1A (MIM
601478; GenBank accession number Q9UBC5), the my-
osin light-chain genes (MLC1SA [MIM 160781]), and
MYL6, all of which were considered good candidates
for hearing loss. MYO1A, also known as “brush border
myosin-I,” is a particularly strong candidate, as it is a
member of the myosin superfamily, which was among
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the first family of proteins found to be associated with
hearing loss and is considered to play a major role in
hair-cell function (Friedman et al. 1999). Mutations in
shaker1 mutant mice and human USH1B (MIM 276903)
were identified in the myosin VIIA (MYO7A [MIM
276903]) gene simultaneously; not long afterward, forms
of both dominant and recessive hearing loss were found
with MYO7A mutations (Gibson et al. 1995; Weil et al.
1995; Liu et al. 1997a, 1997b). Mutations in the un-
conventional myosin VI gene, Myo6, were found to be
associated with deafness and vestibular dysfunction in
the Snell’s waltzer (sv) mouse (Avraham et al. 1995).
Subsequently, the myosin VI (MYO6 [MIM 606346])
gene was found to be mutated in a large Italian family
affected by NSAD (Melchionda et al. 2001). A third
unconventional myosin, myosin XVA (MYO15A [MIM
602666]), is associated with the DFNB3 locus on chro-
mosome 17 and the shaker2 mutant mouse (Probst et
al. 1998; Wang et al. 1998). Finally, most recently, it has
been shown that normal hearing in humans requires my-
osin IIIA (MYO3A [MIM 606808]) (Walsh et al. 2002).
For these reasons, we decided to perform mutation
screening of the MYO1A gene not only in patients from
the large Italian kindred mapping to the DFNA48 locus
but also in a large series of 230 hearing-impaired patients
negative for the presence of connexin 26 (GJB2) gene
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Table 1
MYO1A Mutations Identified in
Italian Probands
Exon Nucleotide Amino Acid
3 277C/T R93X
4 349-350A 349-350insCTT
10 916G/A V306M
12 1155G/T E385D
18 1985G/A G662E
18 2021G/A G674D
22 2390C/T S797F
25 2728T/C S910P
mutations and attending the Medical Genetics Service of
IRCCS-CSS Hospital (San Giovanni Rotondo, Italy). In-
clusion criteria were: (a) absence of the most common
mutations within the GJB2 gene after a molecular
screening performed at the Medical Genetics Service of
IRCCS-CSS Hospital, (b) sensorineural hearing loss, and
(c) normal tympanometric evaluation. The series includes
case subjects with a variable degree of hearing loss, rang-
ing from mild to profound, and with a variable age of
onset, from congenital to late onset. Familial records were
not obtained in most cases. The majority of patients came
from central and southern Italy. After obtaining informed
consent, peripheral blood was obtained from all sub-
jects, and DNA was isolated from blood leukocytes ac-
cording to standard methods. An overall number of 23
primer pairs were designed to amplify the 27 coding
exons of the MYO1A gene, including the splice sites
(PCR primer sequences and conditions available upon
request). All amplicons were screened by denaturing high-
performance liquid chromatography (DHPLC), and
those showing an abnormal chromatographic profile
were subsequently sequenced. DHPLC was performed
on a WAVE Nucleic Acid Fragment Analysis System
HSM (Transgenomic), according to supplier protocols.
DHPLC data analysis was based on a subjective com-
parison of sample and reference chromatograms. PCR
products that showed an abnormal chromatographic
profile on DHPLC analysis were sequenced directly on
an automated sequencer (ABI 377 and 3100; Perkin El-
mer) by use of the ABI-PRISM big-dye Terminator Cycle
Sequencing Ready Reaction kit (Perkin Elmer). For evo-
lutionary analysis, a multiple-sequence alignment (MSA)
of 42 homologous myosins, obtained from the HOM-
STRAD database (Mizuguchi et al. 1998), was used
(available upon request). The evolutionary analysis was
carried out by use of the ConSurf Web server, which uses
the Rate4Site algorithm for estimating the evolutionary
rates at each amino acid site (Pupko et al. 2002; Glaser
et al. 2003). Rate4Site uses the maximum likelihood (ML)
principle, using as input a neighbor-joining phylogenetic
tree (Saitou and Nei 1987) constructed from the MSA.
The ML method considers the tree topology and branch
lengths, as well as the underlying stochastic process of
the evolution of the sequences. For proteins with a
known three-dimensional (3D) structure, the ConSurf
server is used (Glaser et al. 2003). The rates of evolution
among homologous proteins are mapped onto the 3D
structure of one of the homologous proteins. Surface
patches of slowly evolving—also referred to as “evolu-
tionarily conserved” or simply “conserved”—residues
are occasionally functionally important. Similarly, slowly
evolving buried residues are usually important for main-
taining the protein’s 3D structure. The ConSurf scores
range 1–9: 1 is for rapidly evolving (variable) sites, color
coded in turquoise; 5 is the average, color coded as
white; and 9 is for slowly evolving (evolutionarily con-
served) sites, color coded in maroon.
After the mutational screening, we were able to iden-
tify a nonsense mutation, a trinucleotide insertion, and
six missense mutations within theMYO1A gene, as sum-
marized in table 1.
The nonsense mutation is due to a CrT nucleotide
change at position 277 of the cDNA (relative to the ATG,
designated “1”) (fig. 1A). This substitution changes the
residue arginine to a stop signal at position 93 of the
protein (R93X) in the motor domain and can be easily
detected by PCR digestion, since it destroys an AvaII
restriction site. (fig. 1B). This mutation was present in
a male patient from southern Italy affected by a moderate-
to-severe bilateral sensorineural hearing impairment, who
received this mutant allele from his mother. She states she
has normal hearing, but no audiological evaluation has
been carried out or is currently obtainable. The healthy
brother of the proband does not carry the R93X mutant
allele.
A CTT insertion was detected between nucleotides
349 and 350 (349-350insCTT) of the MYO1A cDNA
sequence. This insertion results in the addition of a serine
residue after position 116 of the protein between a serine
residue and a tyrosine in a region of the protein that
is conserved across species (fig. 1C). According to the
3D model, this mutation adds a residue in the middle
of a buried a-helix, which may cause structural damage
(fig. 2). This mutation was found in a female patient
from Sicily who is affected by a moderate-to-severe bi-
lateral sensorineural hearing loss, particularly in the high-
frequency range. Family history is positive in the mater-
nal branch, with a dominant pattern of transmission with
variable penetrance and/or expressivity.
A GrA nucleotide change was detected at position 916
of the cDNA. This change leads to an amino acid valiner
methionine substitution at position 306 of the protein
(V306M) and was detected in a male patient, age 40
years, who was affected by bilateral severe hearing loss,
involving mainly high frequencies. We analyzed this and
other missense mutations with ConSurf, an algorithmic
tool that provides an estimation of the degree of con-
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Figure 1 Nonsense and frameshift mutations. A, Sequence data of the nonsense R93X mutation. B, Results showing the presence of
R93X after AvaII restriction enzyme digestion. The presence of the mutation destroys a restriction site. ND p not digested; M p mutated; N
p normal. C, Electrophoretic results showing the presence of the 349-350insCTT mutation. Fluorescent primers were designed and used for
detecting the presence of the insertion in a 3100 ABI Prism Capillary Electrophoresis.
servation of each residue relative to its homologues (Gla-
ser et al. 2003). The V306M replacement affects a resi-
due of average conservation, which suggests that this
mutation may not be harmful (fig. 2). However, addi-
tional functional data are required to determine if this
mutation is truly causative or if it is a rare variant.
A missense mutation (E385D) due to a GrT nucleo-
tide change at position 1155 ofMYO1A cDNA sequence
was detected in a 10-year-old female patient from central
Italy. In this case, the patient exhibits sensorineural hear-
ing loss with an early onset (age 2 years); the degree of
hearing loss was moderate to severe in the left ear but
mild in the right one, and the patient does not use hear-
ing aids. A family history of moderate-to-severe pro-
gressive hearing loss was present in the maternal branch,
transmitted as an autosomal dominant trait with variable
penetrance and/or expressivity. The nucleotide change
leads to an amino acid substitution from glutamic acid
to aspartic acid, both negatively charged residues that
differ from each other by one methylene group (CH2).
However, glutamic acid at position 385 is highly con-
served according to the ConSurf analysis and, therefore,
is predicted to play an essential functional role in MYO1A
(fig. 2). Furthermore, the 3D model demonstrates that
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Figure 2 Ribbon representation of a 3D model of the MYO1A motor domain. The model was obtained using the experimentally determined
structure of Dictyostelium discoideum myosin-IE as a template (Kollmar et al. 2002). The two motor domains share 45% sequence identity
with each other. The homology-model building was carried out using a pairwise alignment of these two proteins and the Nest facility of the
Jackal protein structure modeling package. The degree of conservation of the residues in MYO1A was analyzed using ConSurf (Glaser et al.
2003); residue conservation scores, calculated using 42 homologous sequences, are color coded onto the structure of MYO1A (see key). ConSurf
assigns amino acid conservation grades in range 1–9, where 9 is maximal conservation and 1 is minimal conservation—that is, highly variable.
The residues mutated in the MYO1A motor domain are shown using ball-and-stick representation (insets).
the highly conserved E385 residue lies in close proximity
to the transition state analog MgADP•VO4 in the ATP-
binding site. Its negatively charged carboxyl end may form
a hydrogen bond with a highly conserved arginine 158
(R158). Therefore, even a conservative replacement to an
aspartic acid may destabilize the electrostatic interac-
tions within the ATP-binding site and is likely to affect
ATPase activity.
Another GrA change affecting nucleotide 1985 was
detected in a 5-year-old male patient affected by a mild
sensorineural hearing loss. This change leads to a sub-
stitution of an exposed glycine residue with glutamic
acid at position 662 (G662E) that appears to be variable
in nature (fig. 2). Thus, functional assays must be per-
formed to determine whether this change is a mutation
or polymorphism.
We also detected a GrA transition at position 2021
of the cDNA sequence, which replaces a glycine (GGC)
with an aspartic acid (GAC) at residue 674 of the protein
(G674D). According to the ConSurf analysis, this change
affects a residue that is exclusively conserved among all
the homologues (fig. 2). In the 3D model, G674 forms a
b-hairpin through main-chain interactions with lysine 677
(K677). A small amino acid, such as glycine, is crucial
for forming this b-turn. Replacement by a large amino
acid, such as an aspartic acid, is likely to cause steric
hindrance that can destabilize the b-core and the 3D-
fold of the protein. Therefore, this mutation may cause
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Figure 3 Myo1a and Myo6 in mouse inner ear. At each of E14,
E16, E18, and P0, one RNA preparation was used to amplify the two
genes by RT-PCR. Amplifications were carried out with () and with-
out () reverse transcriptase, by use of inner-ear RNA, genomic DNA
(G), and H20 control (H). TheMyo1a fragment of 417 bp is the predicted
size of the amplicons spanning Myo1a exons 13–16. Predictions were
verified by sequencing the products. The Myo6 amplification (Ahituv
et al. 2000) was used as a positive control for inner-ear expression.
Fragment of 385 bp and 880 bp represents the predicted sizes of these
amplicons from cDNA and genomic DNA, respectively.
structural, rather than functional, damage. This mutation
has been detected in a male patient from southern Italy,
age 13 years, who is affected by a moderate-to-severe
bilateral hearing loss. No family records are available.
A missense mutation (S797F) due to a CrT nucleotide
change at position 2390 of the MYO1A cDNA sequence
was detected in a patient affected by a moderate sensori-
neural hearing loss with an early onset (age 6 years). The
patient inherited the mutation from his hearing-impaired
father, with a classical autosomal dominant pattern of
transmission. The nucleotide change leads to an amino
acid substitution of a serine residue with a phenylalanine
(fig. 2) in a region that is unique; therefore, too few
homologues can be collected to perform a reliable evo-
lutionary analysis.
Finally, a TrC change affecting nucleotide 2728 was
detected in a male patient from southern Italy, affected
by a severe bilateral sensorineural hearing loss. Family
records are negative. This change leads to a substitution
to a proline at position 910 (S910P) in the myosin tail
domain (fig. 2) in a region with few homologues. Nev-
ertheless, this change can create a “kink” that may de-
stabilize the tail domain.
In addition, the analysis of the coding region and exon-
intron boundaries of the MYO1A gene identified five in-
tronic nucleotide variants and one third-base change in
the coding region that either do not affect the MYO1A-
predicted protein or did not segregate with deafness (data
not shown). No mutation has been thus far identified in
the coding region or exon-intron boundaries of the
MYO1A gene in the large multigenerational Italian fam-
ily mapping to DFNA48. We are now working to rule
out the possible presence of a deletion or of a mutated
allele in the genomic regions not yet analyzed, such as
introns or promoters. Alternatively, one of the other can-
didate genes in the region may lead to deafness in the
large family.
The presence of the eight above-mentioned mutations
was tested for on 200 normal chromosomes of individ-
uals coming from the same geographical area of patients.
None of them were detected in any normal chromosome.
To evaluate Myo1a (GenBank accession number
AF009960) expression in the inner ear, we used RT-PCR
analysis of RNA extracted from mouse inner ears and
cochlea. The predicted genomic structure of the Myo1a
gene was obtained from the Ensembl Mouse Genomic
Browser. Primers spanning three introns and covering a
total of 1.7 kb of genomic sequence were chosen so that
the 417-bp cDNA PCR product could be distinguished
from genomic DNA (primers available on request). A
strong band was obtained in cDNA derived from E14,
E16, E18, and P0 inner ears (fig. 3) and confirmed by
direct sequencing. Further dissection of cochlea from P0
revealed the same transcript as well (data not shown).
In conclusion, the human MYO1A gene maps within
the DFNA48 region and was an excellent candidate be-
cause of its chromosomal location, cochlear expression,
and function. A nonsense mutation, a trinucleotide in-
sertion leading to an additional amino acid, and six mis-
sense mutations have been identified in eight unrelated
patients coming from central and southern Italy and af-
fected by sensorineural bilateral hearing loss of variable
degree, usually ranging from moderate to severe but
never profound. In some cases, it was possible to trace
a clear family history of hearing loss, confirmed also by
audiometric evaluations. In contrast, for most of our
patients, it was not possible to access clinical informa-
tion and/or perform any audiological evaluation of the
patients’ relatives; therefore, we have a lack of accurate
information on the audiological status of parents and
relatives. In the case of our patient with the R93X non-
sense mutation, such an evaluation of his relatives may
have important relevance. The proband inherited the mu-
tant allele from his mother, who claims she has normal
hearing. So far, we do not have any audiological exam-
ination of the mother, and she is not available for future
investigations. Very frequently, with progressive forms
of hearing loss, individuals refer to themselves as having
normal hearing even if audiological evaluations dem-
onstrate that their thresholds are not normal. Thus, in
this case of the patient with the R93X allele, the “normal
hearing” claimed by the proband’s mother could be ex-
plained by a lower threshold considered normal by the
mother herself. However, if the mother were tested and
an audiological examination revealed normal hearing, it
would suggest reduced penetrance, as is known to occur
in other forms of hereditary hearing loss or other genetic
diseases transmitted as an autosomal dominant trait.
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The identification of a nonsense mutation, an in-frame
insertion, and several missense mutations in theMYO1A
gene associated with hearing loss suggests a crucial role
for the MYO1A protein in hearing. For the six missense
mutations found, we used ConSurf to analyze the im-
portance of each mutated residue for maintaining the
structure or function of the protein. This algorithmic tool
provides an estimate of the evolutionary rate at each
amino acid site, using a statistically rigorous approach
that takes into account the phylogenetic relationships
within the protein family. Two missense mutations de-
scribed here, E385D and G674D, affect residues that are
slowly evolving and, therefore, may play a fundamental
role for the proper function or structure of the protein.
On the basis of our analysis, we predict that four of six
missense mutations found contribute to MYO1A-as-
sociated hearing loss. A functional analysis of all mis-
sense mutations is required to further validate their role
in deafness. In addition, none of the missense mutations
reported here have been detected in normal chromosomes.
The myosin I isozymes were the first unconventional
myosins to be purified and have been implicated in vari-
ous motile processes, including organelle translocation,
ion-channel gating, and cytoskeletal reorganization, but
their exact cellular functions are still unclear. All mem-
bers of the myosin I family, from yeast to man, have
three structural domains: a catalytic head domain that
binds ATP and actin, a tail domain believed to be in-
volved in targeting the myosins to specific subcellular
locations, and a junction or neck domain that connects
them and interacts with light chains. Brush border myo-
sin-I (MYO1A) is a major component of the actin-rich
cytoskeleton of the brush border surface in intestinal
epithelial cells and is strongly expressed in the large and
small intestine (Skowron et al. 1998). The expression of
Myo1a was barely detected by RT-PCR in RNA ex-
tracted from neonatal mouse utricles, a component of the
vestibular system (Dumont et al. 2002). We were suc-
cessful in amplifying Myo1a from mouse inner-ear cDNA
at several developmental stages and from cochlea at P0.
A role for MYO1A in the inner ear has not been estab-
lished, although the actin-rich cytoskeletal structure of
intestinal and inner-ear cells, including hair cells and
supporting cells, are similar. In the intestine, MYO1A
may play a role in membrane trafficking (Skowron and
Mooseker 1999). As myosin VI is predicted to have sim-
ilar roles of transport in the kidney and inner ear (Tux-
worth and Titus 2000), the same may hold true for
MYO1A. Additional studies are required to better un-
derstand the pathogenic mechanisms leading to hearing
loss as a consequence of an MYO1A mutant allele.
MYO1A is the first myosin I family member found to
be linked to human hereditary deafness, now joining
another class I myosin that was found to play an essen-
tial role in the auditory transduction mechanism, myo-
sin-1c (MYO1C [MIM 606538]) (Holt et al. 2002). It
will be interesting to investigate the potential role of other
cochlear-expressing myosin I genes, such asMYO1C and
MYO1E (MIM 601479), in hearing loss (Dumont et al.
2002).
Finally, the identification of at least six different mu-
tations suggests that this gene may be a significant con-
tributor to autosomal dominant cases. In fact, only a
few genes among those so far described present with
mutations in more than a single family (Petersen 2002).
Additional studies are required to definitively prove the
real contribution of MYO1A to deafness in a population
base.
Acknowledgments
This work was supported by Telethon (grant E.813) (to P.G.);
the Istituto Banco di Napoli (to P.G.); FIRB grant (to P.G.) and
Cofin 2002 (to P.G.); the European Economic Community
(QLG2–1999–00988) (to K.B.A.); and the Ministry of Science,
Culture, and Sports (to K.B.A.). The authors thank E. Lapi
(Florence) and M. Mattina (Catania) for their help in providing
clinical information on two patients included in the study and
Nir Ben-Tal and Meytal Cohen (Tel Aviv).
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
ConSurf Server, http://consurf.tau.ac.il/ (for estimating the evo-
lutionary rates at amino acid sites)
Ensembl Genome Browser, http://www.ensembl.org/Mus
_musculus/ (for mouse genome)
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for human
MYO1A [accession number Q9UBC5] and mouse Myo1a
[accession number AF009960])
Hereditary Hearing Loss Homepage, http://www.uia.ac.be/
dnalab/hhh/ (for the genetics of hereditary hearing
impairment)
Homologous Structure Sequence Alignment (HOMSTRAD),
http://www-cryst.bioc.cam.ac.uk/˜homstrad/
Jackal, http://trantor.bioc.columbia.edu/˜xiang/jackal/#nest (for
protein structure modeling)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for RARG, PFDN5, MYO1A,
MLC1SA, MYL6, USH1B, MYO7A, MYO6, MYO15A,
MYO3A, MYO1C, and MYO1E)
References
Ahituv N, Sobe T, Robertson NG, Morton CC, Taggart RT,
Avraham KB (2000) Genomic structure of the human un-
conventional myosin VI gene. Gene 261:269–275
Avraham KB, Hasson T, Steel KP, Kingsley DM, Russell LB,
Mooseker MS, Copeland NG, Jenkins NA (1995) The mouse
Snell’s waltzer deafness gene encodes an unconventional myo-
Reports 1577
sin required for the structural integrity of inner ear hair cells.
Nat Genet 11:369–375
D’Adamo P, Pinna M, Capobianco S, Cesarani S, D’Eus-
tacchio A, Fogu P, Carella M, Seri M, Gasparini P (2003)
A novel autosomal dominant non-syndromic deafness lo-
cus (DFNA48) maps to 12q13–q14 in a large Italian fami-
ly. Hum Genet 112:319–320
Dumont RA, Zhao YD, Holt JR, Bahler M, Gillespie PG (2002)
Myosin-I isozymes in neonatal rodent auditory and vestibu-
lar epithelia. J Assoc Res Otolaryngol 3:375–389
Friedman TB, Sellers JR Avraham KB (1999) Unconventional
myosins and the genetics of hearing loss. Am J Med Genet
89:147–157
Gibson F, Walsh J, Mburu P, Varela A, Brown KA, Antonio
M, Beisel KW, Steel KP, Brown SD (1995) A type VII myosin
encoded by the mouse deafness gene shaker-1. Nature 374:
62–64
Glaser F, Pupko T, Paz I, Bell RE, Bechor-Shental D, Martz E,
Ben-Tal N (2003) ConSurf: identification of functional regions
in proteins by surface-mapping of phylogenetic information.
Bioinformatics 19:163–164
Holt JR, Gillespie SK, Provance DW, Shah K, Shokat KM, Corey
DP, Mercer JA, Gillespie PG (2002) A chemical-genetic strat-
egy implicates myosin-1c in adaptation by hair cells. Cell
108:371–381
Kollmar M, Durrwang U, Kliche W, Manstein DJ, Kull FJ (2002)
Crystal structure of the motor domain of a class-I myosin.
EMBO J 21:2517–2525
Liu X-Z, Walsh J, Mburu P, Kendrick-Jones J, Cope MJ, Steel
KP, Brown SD (1997a) Mutations in the myosin VIIA gene
cause non-syndromic recessive deafness. Nat Genet 16:188–
190
Liu X-Z, Walsh J, Tamagawa Y, Kitamura K, Nishizawa M,
Steel KP, Brown SD (1997b) Autosomal dominant non-syn-
dromic deafness caused by a mutation in the myosin VIIA
gene. Nat Genet 17:268–269
Melchionda S, Ahituv N, Bisceglia L, Sobe T, Glaser F, Ra-
bionet R, Arbones ML, Notarangelo A, Di Iorio E, Carella
M, Zelante L, Estivill X, Avraham KB, Gasparini P (2001)
MYO6, the human homologue of the gene responsible for
deafness in Snell’s waltzer mice, is mutated in autosomal
dominant nonsyndromic hearing loss. Am J Hum Genet 69:
635–640
Mizuguchi, K, Deane CM, Blundell TL, Overington, JP (1998)
HOMSTRAD: a database of protein structure alignments for
homologous families. Protein Sci 7:2469–2471
Petersen MB (2002) Non-syndromic autosomal-dominant deaf-
ness. Clin Genet 62:1–13
Probst FJ, Fridell RA, Raphael Y, Saunders TL, Wang A, Liang
Y, Morell RJ, Touchman JW, Lyons RH, Noben-Trauth K,
Friedman TB, Camper SA (1998) Correction of deafness in
shaker-2 mice by an unconventional myosin in a BAC trans-
gene. Science 280:1444–1447
Pupko T, Bell RE, Mayrose I, Glaser F, Ben-Tal N (2002)
Rate4Site: an algorithmic tool for the identification of func-
tional regions in proteins by surface mapping of evolution-
ary determinants within their homologues. Bioinformatics
18:S71–S77
Saitou N, Nei M (1987) The neighbor-joining method: a new
method for reconstructing phylogenetic trees. Mol Biol Evol
4:406–425
Skowron JF, Bement WM, Mooseker MS (1998) Human brush
border myosin-I and myosin-Ic expression in human intestine
and Caco-2BBe cells. Cell Motil Cytoskeleton 41:308–324
Skowron JF, Mooseker MS (1999) Cloning and characterization
of mouse brush border myosin-I in adult and embryonic in-
testine. J Exp Zool 283:242–257
Tuxworth RI, Titus MA (2000) Unconventional myosins: an-
chors in the membrane traffic relay. Traffic 1:11–18
Walsh T, Walsh V, Vreugde S, Hertzano R, Shahin H, Haika
S, Lee MK, Kanaan M, King MC, Avraham KB (2002) From
flies’ eyes to our ears: mutations in a human class III myosin
cause progressive nonsyndromic hearing loss DFNB30. Proc
Natl Acad Sci USA 99:7518–7523
Wang A, Liang Y, Fridell RA, Probst FJ, Wilcox ER, Touchman
JW, Morton CC, Morell RJ, Noben-Trauth K, Camper SA,
Friedman TB (1998) Association of unconventional myosin
MYO15 mutations with human nonsyndromic deafness
DFNB3. Science 280:1447–1451
Weil D, Blanchard S, Kaplan J, Guilford P, Gibson F, Walsh J,
Mburu P, Varela A, Levilliers J, Weston MD, Kelley PM,
Kimberling WJ, Wagenaar M, Levi-Acobas F, Larget-Piet D,
Munnich A, Steel KP, Brown SDM, Petit C (1995) Defective
myosin VIIA gene responsible for Usher syndrome type 1B.
Nature 374:60–61
